pharma · Diphtheria · Diabetes Mellitus, Type 2
Sanofi Pasteur MSD
Sanofi Pasteur
Sanofi Pasteur is a pharma organization headquartered in LYON, FR. Primary therapeutic focus areas include Diphtheria, Diabetes Mellitus, Type 2, Japanese Encephalitis, Rabies, Hemophilia A. NovaPharmaNews links 83 clini
France, LYON HQ
363 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- France, LYON
- Employees
- 363
- Programs
- 2
- Drugs
- 44
- Patents
- 0
Venglustat GZ402671
Phase 3 · small molecule · Congenital Cystic Kidney Disease
Venglustat GZ402671 for Congenital Cystic Kidney Disease is a Phase 3 program (small_molecule) at Sanofi Pasteur with 1 ClinicalTrials.gov record(s).
Internal code LTS15823
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Sanofi Pasteur
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Congenital Cystic Kidney Disease
- Status
- terminated
- Trials
- 1